Allurion Technologies’ (ALUR) “Buy” Rating Reiterated at Roth Mkm

Roth Mkm restated their buy rating on shares of Allurion Technologies (NYSE:ALUR) in a research note issued to investors on Friday morning,Benzinga reports. Roth Mkm currently has a $16.00 price objective on the stock.

Separately, Chardan Capital restated a “neutral” rating and set a $2.50 target price on shares of Allurion Technologies in a report on Friday.

Allurion Technologies Trading Up 57.7 %

ALUR stock opened at $3.60 on Friday. Allurion Technologies has a 12-month low of $2.15 and a 12-month high of $98.75. The company has a market cap of $17.24 million, a PE ratio of -0.30 and a beta of -0.59. The stock has a 50-day moving average price of $4.00 and a two-hundred day moving average price of $10.10.

Institutional Trading of Allurion Technologies

A hedge fund recently raised its stake in Allurion Technologies stock. Geode Capital Management LLC lifted its stake in shares of Allurion Technologies Inc. (NYSE:ALUR) by 40.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 516,330 shares of the company’s stock after purchasing an additional 149,484 shares during the period. Geode Capital Management LLC owned about 0.80% of Allurion Technologies worth $317,000 as of its most recent filing with the SEC. 21.39% of the stock is currently owned by hedge funds and other institutional investors.

About Allurion Technologies

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.